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Modulation in vitro and in vivo of cytotoxicity but not cellular levels
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Summary The role of the calmodulin inhibitor trifluoperazine (TFP) in modulating the cellular levels and
cytotoxicity in vitro and antitumour effects in vivo of doxorubicin (DOX), was evaluated in progressively
DOX-resistant (5- to 40-fold) sublines of B16-BL6 mouse melanoma. In parental-sensitive B16-BL6 cells
treated for 3 h, the IC50 of DOX was 0.1pgml- 1, and a <2-fold enhancement in DOX cell kill in the
presence of a noncytotoxic concentration of 5 pM TFP was observed. However, in the DOX-resistant sublines,
the IC50 was 0.7 to 5.0 pgml - DOX in the absence of 5plM TFP and 0.3 to 0.7 pgml - DOX in the
presence of 5p,M TFP. The 2- to 7.5-fold decrease in the IC50 of DOX in the presence of 5pM TFP, was
dependent on the level of DOX-resistance in the various sublines. Compared to parental-sensitive cells, a 2-
fold decrease in DOX-accumulation was evident only in the 40-fold DOX-resistant subline. Further, maximal
enhancement (50%) of cellular DOX accumulation in the presence of 5 pM TFP was observed only in the 40-
fold resistant cells treated with 5.0,pgml- I DOX. Retention of DOX in the 40-fold resistant subline was only
20% lower than similarly treated sensitive cells, and the inclusion of TFP increased DOX retention < 10-
15%. Antitumour studies in mice with experimental pulmonary metastases revealed that although DOX and
DOX plus TFP had similar antitumour activity with the parental sensitive B16-BL6 cells, the combination of
DOX plus TFP was significantly more effective than DOX alone with the DOX-resistant sublines. No overt
toxicity was observed in normal mice treated with doses of TFP, DOX or DOX plus TFP used for in vivo
chemotherapy studies. Results from this study suggest that gross cellular DOX levels do not appear to
correlate with the magnitude of resistance, and the effects of TFP in modulating DOX resistance is possibly
due to mechanisms other than mere alterations in cellular drug accumulation and/or retention.
The characterization of multidrug resistant cells from a
pharmacokinetic, biochemical and genetic standpoint is cur-
rently an area of active investigation (Riordan & Ling,
1985). Clinically, an understanding of the multidrug resistant
phenotype is of far reaching importance in the design of
novel therapeutic strategies, since the pattern of cross-
resistance in these cells encompasses a number of other
potent antitumour drugs (Riordan & Ling, 1985). Doxo-
rubicin (Adriamycin), an anthracycline antitumour antibiotic
is one of the most active agents used in the successful
chemotherapy of leukemias and solid tumours (Carter,
1975). The cellular effects of doxorubicin (DOX) contribut-
ing towards a cytotoxic effect are clearly multifactorial
(Meyers, 1982) and studies with DOX-resistant tumour
models with relatively high levels of resistance (>50-fold)
have suggested that reduced accumulation and/or retention
of DOX is a primary mechanism for the expression of
resistance (Dano, 1976; Skovsgaard, 1978; Inaba et al.,
1979). Studies addressing the role of reduced drug retention
in multidrug resistant cells have suggested that the M,
150,000-180,000 membrane glycoprotein (P-glycoprotein) is
involved in the active drug extrusion process (Gerlach et al.,
1986). Although attempts to relate cellular DOX levels with
cytotoxic effects have demonstrated that impaired drug
uptake is a characteristic of cells with high levels of acquired
DOX-resistance, there is however little correlation between
DOX accumulation characteristics and degree of resistance
(Ganapathi et al., 1986, 1988).
The observation that calmodulin inhibitors and calcium
antagonists (Tsuruo et al., 1982; Ganapathi & Grabowski,
1983) can markedly alter the cytotoxic effects of DOX and
cross-resistant drugs in cells with acquired DOX resistance,
has provided circumstantial evidence for the role of calcium
regulation in multidrug resistance. Early studies on modula-
tion of cytotoxicity by these calcium modifiers suggested
their role to be due to enhanced drug uptake and/or
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retention (Tsuruo et al., 1982; Ganapathi & Grabowski,
1983). However, it has been recently demonstrated that the
effects of the calmodulin inhibitor trifluoperazine (TFP) in
DOX-resistant cells is possibly due to mechanism(s) other
than mere modulation of gross drug levels (Ganapathi et al.,
1986, 1988). Characterization of cells with acquired DOX-
resistance and the effects of calcium modifiers have
traditionally used models with high levels of resistance, and
the relevance of these findings to low levels of resistance
which are likely to be encountered clinically is unknown. We
have recently developed progressively DOX-resistant (5- to
40-fold) B16-BL6 mouse melanoma cells with the multidrug
resistant phenotype (Ganapathi, et al., 1987) and using this
model system, in the present study, we have determined the
characteristics of DOX cellular pharmacokinetics (accumu-
lation and retention) and cytotoxicity in vitro, antitumour
activity of DOX in vivo, and the role of TFP in modulating
these effects.
Materials and methods
The isolation of progressively DOX-resistant B16-BL6 mouse
melanoma cells adapted to grow in vitro, in the presence of
0.025, 0.05, 0.1 and 0.25 jgml- 1 DOX, and identified as
B16-BL6/DOXO.025, B16-BL6/DOXO.05, B16-BL6/DOXO.1
and B16-BL6/DOXO.25 respectively has been previously des-
cribed (Ganapathi, et al., 1987). The various DOX-resistant
sublines B16-BL6/DOX0.025, B16-BL6/DOXO.05, B16-BL6/
DOXO.1 and B16-BL6/DOXO.25 were approximately 5-, 10-,
20- and 40-fold resistant respectively compared to parental
sensitive B16-BL6 cells (B16-BL6/S). The parental sensitive
and DOX-resistant sublines were maintained as in vitro
monolayer cultures at 37C in a humidified 5% CO2 plus
95% air atmosphere using Eagle's minimum essential
medium (E-MEM) with Hanks salts supplemented with non-
essential amino acids, sodium pyruvate, vitamins, 2 mm L-
glutamine and 5% foetal bovine serum (FBS). All media and
supplements were obtained from M.A. Bioproducts,
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Walkersville, MD and FBS was from Hyclone Laboratories,
Logan, UT. Cells were subcultured weekly using 0.25%
trypsin-0.02% EDTA. The doubling time in vitro of parental
sensitive and progressively DOX-resistant sublines of B16-
BL6 melanoma cells was 16-18h.
Trifluoperazine was a gift of Dr Carl Kaiser, Smith, Kline
and French Laboratories, Philadelphia, Pennsylvania.
Doxurubicin cytotoxicity in vitro
Log-phase monolayer cultures of the parental-sensitive and
5- to 40-fold DOX-resistant sublines of B16-BL6 melanoma
cells in supplemented E-MEM with 5% FBS were treated
with 0.05, 0.1, 0.25, 0.5, 1.0, 2.0 and 5.O4ugml-1 of DOX
in the absence or presence of 5 pM TFP. Stock solutions of
DOX and TFP were prepared in sterile glass distilled water,
and working dilutions prepared in supplemented E-MEM.
Following incubation for 3h at 37°C in a humidified 5%
CO2 plus 95% air atmosphere, cell monolayers were washed
twice with sterile 0.9% sodium chloride solution, trypsinized
and resuspended in supplemented E-MEM with 5% FBS.
The cells were washed in supplemented E-MEM with 5%
FBS, centrifuged at 80g and resuspended in E-MEM with
5% FBS. Cells in 1 ml of supplemented E-MEM containing
20% FBS and 0.3% agar were plated in triplicate over a
1 ml base layer of supplemented E-MEM containing 20%
FBS and 0.5% agar in 35 x 10-mm Petri dishes. Due to the
variable colony forming efficiency of the sensitive and pro-
gressively DOX-resistant B16-BL6 cells (Ganapathi, et al.,
1987), the following numbers of cells were plated per
35 x 10-mm Petri dish: B16-BL6/S, 2.5 x 104 cells; B16-BL6/
DOXO.025, B16-BL6/DOXO.05 and B16-BL6/DOXO.1,
1 X 104 cells; and B16-BL6/DOXO.25, 5 x 103 cells. After
plating, the Petri-dishes were incubated for 7 days in a
humidified 5% CO2 plus 95% air atmosphere, and colonies
(>50 cells) in control and treated plates counted using an
Omnicon Feature Analysis System II (Bausch and Lomb,
Rochester, NY).
Doxorubicin accumulation in vitro
Log-phase cultures of parental-sensitive (BI6-BL6/S) and
DOX-resistant sublines (B16-BL6/DOXO.05 and B16-BL6/
DOXO.25) harvested from monolayer cultures and resus-
pended at a density of I x 106 cellsml - in supplemented E-
MEM with 5% FBS were treated with 0.5, 1.0 and
5.0 pgml-1 DOX in the absence or presence of 5pM TFP at
37°C, in a humidified 5% CO2 plus 95% air atmosphere.
Duplicate samples (1 x 106 cells) removed at the end of I h
and 3 h of treatment were centrifuged (lOOg) and washed
twice with 7ml of ice-cold 0.85% sodium chloride solution.
After the final wash, cell pellets were mixed thoroughly in a
vortex mixer with 50% ethanol-0.3 N hydrochloric acid,
centrifuged at 700g, and DOX content in the supernatant
determined fluorimetrically (Bachur et al., 1970; Ganapathi,
et al., 1984a,b) in an Aminco-Bowman spectrophotofluoro-
meter (American Instrument Co., Silver Spring, MD) at
excitation and emission wavelengths of 470 nm and 585 nm
respectively. DOX content was computed from a standard
curve prepared with DOX in 50% ethanol-0.3 N hydro-
chloric acid, and expressed as ng 10-6 cells. Thin layer
chromatographic analysis of cell extracts following DOX
treatment revealed no metabolism of parent drug, suggesting
that the fluorimetric analysis represents unchanged cellular
DOX levels.
Doxorubicin retention in vitro
Log phase cultures of B16-BL6/S and B16-BL6/DOXO.25
cells harvested from monolayer cultures were resuspended in
supplemented E-MEM with 5% FBS and pretreated for 1 h
at 37°C. in a humidified atmosphere of 5% CO2 plus 95%
air with 1 pgml - DOX in the absence or presence of 5pM
TFP. Treated cells were then centrifuged, resuspended in
DOX-free medium (supplemented E-MEM with 5% FBS)
with or without 5pM TFP and subsequently incubated at
37°C. Duplicate samples (I x 106 cell) retrieved at the end of
1 h following the pretreatment accumulation phase and sub-
sequently at 30, 60, 90 and 120min during the retention
phase were centrifuged (1OOg) and washed twice with 7ml of
ice-cold 0.85% sodium chloride solution. Cellular DOX
levels were determined fluorimetrically as described earlier
under accumulation experiments and expressed as ng 10-6
cells.
At the concentrations of DOX in the absence or presence
of 5 M TFP utilized for the accumulation and retention
experiments, no changes in viability (based on trypan blue
dye exclusion) compared to untreated controls were observed
in the sensitive or DOX-resistant sublines.
Antitumour activity of doxorubicin in vivo
Male C57BL/6NCr mice, 6-8 weeks old, obtained from the
Animal Genetics and Production Branch, Frederick Cancer
Research Facility, National Cancer Institute, Fort Detrick,
Maryland, were used for the in vivo studies with sensitive
and DOX-resistant B16-BL6 cells. Log-phase cultures of
parental-sensitive (BI6-BL6/S) and DOX-resistant sublines
(Bi6-BL6/DOXO.05 and B16-BL6/DOXO.25) were trypsin-
ised, resuspended in supplemented E-MEM with 5% FBS
and centrifuged (80g). Cells were washed twice at 4°C with
sterile 0.9% sodium chloride solution and recovered by
centrifugation at 80g. Cells from parental sensitive and
DOX-resistant sublines as a single cell suspension
(viability>95% based on trypan blue dye exclusion) at a
density of 3 x 106 cellsml-1 in sterile 0.9% sodium chloride
solution were injected (3 x 105 cells, 0.1 ml/mouse) into the
tail vein of unanesthetised mice in groups of 6-8 matched for
age, weight and sex (day 0). Groups of mice were injected
with 0.9% sodium chloride solution (control), 20mgkg-
TFP, 4mgkg-1 DOX, or 4mgkg-1 DOX plus 20mgkg-1
TFP Q6h x 2 on day 1 and day 2. Mice were killed 21 days
later, and the number of pulmonary metastases in both lungs
from control and treated mice counted under a stereo
dissecting microscope. Each experiment was replicated at
least twice and the median number of metastases determined.
Results and discussion
The effect of trifluoperazine on the cytotoxicity of doxo-
rubicin in parental sensitive and progressively DOX-resistant
sublines of B16-BL6 cells is shown in Table I. In all cell lines
treated with 5pM TFP alone, did not result in appreciable
cytotoxicity compared to the untreated control, and survival
was >90%. The cytotoxic effects of DOX alone were
markedly dose-dependent in sensitive cells and in the
presence of 5pM TFP, <2-fold enhancement in cell kill was
observed. Cell kill with DOX alone was not dose dependent
up to 0.25, 0.5, 1.0 and 2.Opgml-1 DOX in the B16-BL6/
DOXO.025, B16-BL6/DOXO.05, B16-BL6/DOXO.1 and B16-
BL6/DOXO.25 sublines respectively. However, with 2- to 4-
fold increases in drug concentrations, DOX dose-dependent
cytotoxicity was apparent. The effects of TFP in modulating
DOX cytotoxicity was more apparent with the DOX-
resistant sublines, and compared to DOX alone, in the
presence of 5 M TFP, cell kill was related to the dose of
DOX over the concentration range studied. In Figure 1 a
plot of IC50 concentration of DOX in the absence or
presence of 5pM TFP versus the degree of resistance is
shown. Compared to the concentration of DOX alone
producing a 50% reduction in colony formation, in the
presence of 5pM TFP there was approximately a 2.3-, 3.7-,
7- and 7.5-fold reduction in the IC50 of DOX in the B16-
BL6/DOXO.025, B16-BL6/DOXO.05, B16-BL6/DOXO.01 and
B16-BL6/DOXO.25 sublines respectively. These results sug-
gest that effects of TFP in enhancing DOX cytotoxicity areTRIFLUOPERAZINE AND PROGRESSIVE DOXORUBICIN RESISTANCE 337
Table I Effect of TFP on the cytotoxicity of DOX in sensitive and progressively DOX-resistant B16-BL6 mouse
melanoma cells
Survival (% of controOc
Drug concentrationa
5Mm TFP
DOX 0.05gml-1
DOX 0.05 ugml -1+5pMTFP
DOX0.1 gm1-I
DOX0.lpgml-1+5Mm TFP
DOX 0.25pgml-1
DOX 0.25 pgml-1+5Mm TFP
DOX 0.5Mgml-1
DOX 0.5 ugml +5MmTFP
DOX1.0pgml 1
DOX l.0pgml-1+5pMTFP
DOX 2.0 gml -1
DOX 2.0 Mgml-1+5pM TFP
DOX 5.0ugml-1
DOX 5.0 pgml-1+5uM TFP
B16-BL6/ B16-BL6/
B16-BL6/S DOX 0.025 DOX 0.05
B16-BL6/ B16-BL6/
DOX 0.1 DOX 0.25
100+OC 94+4c 94+5c 91 +5c 95+5c
90+6
78+7
32+3
32+3
26+6
15+3
6+1
3+0.2
0.6+0.1
0.3 +0
95+0.5
76+ 5
83+8
60+7
53 +7
41 +0.5
46+0.5
17+0.5
24+6
4+0.5
88+6
81 +8
90+5
69+5
81+7
45+8
61+3
21 +5
33 + 3
7+0.2
96+4 93+4
79+6 95+5
88+5 100+0
46+3 70+8
71 +7 87+6
23+4 36+5
44+3 80+7
9+3 17+3
16+0.6 53+2
3+0.6 5+0.9
aCells were treated with various concentrations of DOX in the absence and presence of 5gM TFP for 3h, washed and
plated in soft-agar; bDue to the variable colony forming efficiency of the sensitive and progressively DOX-resistant sublines
(Ganapathi et al., 1987) the following numbers of cells were plated per 35 x 10-mm Petri-dish: B16-BL6/S, 2.5 x 104 cells
(colony forming efficiency of untreated control=3%), B16-BL6/DOX0.025, B16-BL6/DOX0.05 and B16-BL6/DOXO.1,
Xl104 cells (colony forming efficiency of untreated control=30%), B16-BL6/DOXO.25, Sx103 cells (colony forming
efficiency of untreated control=75%); cValues are expressed as mean+s.e. from triplicate experiments. Survival is based on
colony counts.
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Figure 1 Relationship between IC50 concentration of DOX
with or without 5Mm TFP in sensitive and progressively DOX-
resistant sublines of B16-BL6 mouse melanoma. The estimated
IC50 concentration of DOX was determined by regression
analysis of data from Table I. Isolation of B16-BL6/DOXO.025,
B16-BL6/DOXO.05, B16-BL6/DOXO.1, and B16-BL6/DOXO.25
sublines was carried out after parental sensitive (B16-BL6/S) cells
were adapted to grow in vitro in the presence of 0.025, 0.05, 0.1,
and 0.25 gml-1 DOX respectively (Ganapathi et al., 1987). The
various DOX-resistant sublines, B16-BL6/DOXO.025, B16-BL6/
DOXO.05, B16-BL6/DOXO.1, and B16-BL6/DOXO.25, were
approximately 5-, 10-, 20-, and 40-fold resistant, respectively,
compared to the B16-BL6/S cells (Ganapathi, et al., 1987).
related to the level of DOX resistance in cells with acquired
DOX resistance.
Cellular accumulation of DOX in the absence or presence
of 5MM TFP in B16-BL6/S, B16-BL6/DOXO.05 and B16-
BL6/DOXO.25 resistant sublines is presented in Figure 2. In
cells treated with 0.5pgml-1 and l.Oigml-1 DOX alone,
drug accumulation was concentration and time dependent
and DOX accumulation in the B16-BL6/DOXO.05, cells was
comparable to the sensitive cells (<10% different) and TFP
had relatively little effect in enhancing drug accumulation in
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Figure 2 Cellular accumulation of DOX without TFP (E) or
with 5Mm TFP (1) at 1 h and 3h in sensitive and progressively
DOX-resistant B16-BL6 cells treated with 0.5 gml-1 DOX (A),
1.Ogml - DOX (B) and 5.O0gmI-1 DOX (C). B16-BL6/S (a),
B16-BL6/DOXO.05, (b) and B16-BL6/DOXO.25, (c). Values are
means of duplicate determinations from replicate experiments,
with a coefficient of variation of <10%.
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both cell types. In contrast, the B16-BL6/DOXO.25 subline
accumulated approximately 20 to 25% less DOX than the
sensitive cells when treated with 0.5,ugml-l and 1.Ojigml-l
DOX, and in the presence of 5pM TFP cellular DOX levels
were enhanced - 1.2-fold.
Reduced accumulation of DOX in the resistant sublines
compared to sensitive cells was most apparent when exposed
to 5.0 jgml-1 DOX. At 3 h with the Bl 6-BL6/DOXO.05 cells
and at both I h and 3 h periods with the B16-BL6/DOXO.25
cells, cellular DOX levels were 1.3- to 2.0-fold lower than in
similarly treated B16-BL6/S cells. Although TFP had little
effect in enhancing DOX accumulation in B16-BL6/S cells,
at 3 h with 5.0Mgml-1 DOX plus 5 gM TFP, cellular DOX
levels in the B16-BL6/DOXO.05 and B16-BL6/DOXO.25 cells
were 1.25-fold and 1.5-fold higher respectively.
Statistical analysis of the data using analysis of variance
and Bonferroni t-tests (Neter & Wasserman, 1974) to
identify differences in DOX accumulation and the effect of
TFP in the various cell lines revealed the following: (a) in
general, B16-BL6/S was not different from B16-BL6/
DOXO.05, but B16-BL6/S and B16-BL6/DOXO.05 were
different from B16-BL6/DOXO.25 cells; (b) the effect of TFP
on significantly (P<0.05) enhancing DOX accumulation was
apparent at 3h and only in combination with 5.0 gml-1
DOX; and (c) although not statistically significant, effect of
TFP on enhancing cellular DOX accumulation was depen-
dent on the level of resistance at 3 h versus 1 h, with a
tendency for a more pronounced effect in the cell lines with
higher levels of resistance.
The effect of TFP on retention of DOX in B16-BL6/S and
B16-BL6/DOXO.25 cells is shown in Figure 3. In the B16-
BL6/S, cellular retention of DOX at the end of 90-120min
was -55-60%. Further the inclusion of TFP during the 1 h
pretreatment and/or the retention phase did not markedly
alter the amount of DOX retained. However, in B16-BL6/
DOXO.25 cells, DOX retention was 35-40% whether TFP
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was absent or present during the initial accumulation phase.
A minor role for TFP in competing for outward transport of
DOX was apparent, since inclusion of TFP in the extra-
cellular medium during retention increased the level of DOX
retained to 50%.
The antitumour effects in vivo of TFP, DOX and
DOX+TFP against experimental pulmonary metastases of
B16-BL6/S, B16-BL6/DOX0.05 and B16-BL6/DOXO.25 cells
is outlined in Table II. The differences in formation of
experimental pulmonary metastases between sensitive and
resistant sublines of B16-BL6 melanoma in control animals
is in accordance with our earlier data on metastatic behav-
iour of this progressively DOX-resistant model system
(Ganapathi, et al., 1987). The dose and schedule of DOX
and/or TFP for the in vivo studies was based on toxicity
studies in naive mice demonstrating no treatment related
mortality over 60 days. Further, histology of 2 M metha-
crylate sections of the heart stained with haematoxylin and
eosin, revealed no appreciable muscle fibre damage in TFP,
DOX or DOX+TFP treated mice compared to saline
controls. TFP alone had no effect in reducing the tumour
burden with the sensitive and DOX-resistant sublines sug-
gesting that concentrations achieved in vivo are non-
cytotoxic. In mice inoculated with B16-BL6/S, DOX alone
was markedly effective in reducing lung tumour burden, and
the combination of DOX plus TFP was not significantly
more effective than DOX alone. A 2-fold reduction in lung
tumour burden with DOX alone was apparent with the B16-
BL6/DOXO.05 cells, but no antitumour effects were observed
with the B16-BL6/DOXO.25 subline. This difference in res-
ponse could be attributed to the achievable blood levels of
DOX and the 3.6 fold difference in IC50 of DOX alone
between the two resistant sublines, observed in vitro (Figure
1). The combination of DOX+TFP was >3-fold and >2-
fold more effective than DOX alone in reduction of pulmon-
ary metastases with the B16-BL6/DOX0.05 and B16-BL6/
DOXO.25 sublines respectively, and once again the magni-
tude of this response could be related to a <2-fold differ-
ence in the IC50 of DOX in the presence of TFP with these
sublines (Figure 1). The combination of DOX plus TFP was
more effective than DOX alone in the resistant sublines
versus parent sensitive cells, which is in accordance with the
in vitro cytotoxicity data (Table I). Further studies on reduc-
tion in pulmonary metastases following treatment and its
relationship to survival time of mice are currently ongoing.
The role of 'calmodulin inhibitors' and 'calcium antagon-
ists' in modulating DOX- and daunorubicin-resistance in
Table II Effect of the calmodulin inhibitor trifluoperazine on the
chemotherapeutic efficacy of doxorubicin in vivoa
Median number ofpulmonary metastases
Doxorubicin resistance
20
0
I I
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Figure 3 Cellular retention of DOX in the absence or presence
of TFP in B16-BL6/S ( ) and B16-BL6/DOXO.25 (----)
cells. (0) accumulation and retention in the absence of 5 iM
TFP; (A) accumulation in the presence of 5 IM TFP and
retention in the absence of 5JM TFP; (A) accumulation and
retention in the presence of 5 tM TFP. Each point is the mean
value of replicate determinations from at least duplicate experi-
ments, with a coefficient of variation of < 10%.
Treatment
Saline control
Trifluoperazine
20mgkg-1, q 6h (x2)
day 1 and day 2
Doxorubicin
4mgkg-1, q 6h (x2)
day 1 and day 2
Doxorubicin 4mgkg1
plus trifluoperazine
20mgkg-1, q 6h (x2)
day 1 and day 2
B16-BL6/
B16-BL6/S DOXO.05
B16-BL6/
DOXO.25
>500 263 63
>500 355 55
49
9b, c 33b, C, d 23b,c. d
aData from at least duplicate trials with 8 mice per group in each
experiment; bSignificantly different from saline control using Bonfer-
roni t-test, P<0.05; cSignificantly different from trifluoperazine
alone using Bonferroni t-test, P<0.05; dSignificantly different from
doxorubicin alone using Bonferroni t-test, P<0.05.
-TRIFLUOPERAZINE AND PROGRESSIVE DOXORUBICIN RESISTANCE 339
vitro and in vivo has been a subject of considerable interest
in recent years (Tsuruo et al., 1982, 1983; Slater et al., 1982;
Ganapathi & Grabowski, 1983, 1988; Ganapathi et al.,
1984a,b, 1985; Kessel & Wilberding, 1985; Krishan et al.,
1985; Harker et al., 1986). The rationale for using the
calcium modifiers was to enhance cellular anthracycline
levels and consequently the cytotoxic effects. Although
models exhibiting high levels of anthracycline resistance
(Dano, 1976; Skovsgaard, 1978, Inaba et al., 1979) and
progressive resistance (Wheeler et al., 1982; Siegfried et al.,
1983) demonstrate reduced drug accumulation, it is however
apparent that the magnitude of reduction in cellular drug
levels does not account for the degree of resistance
(Ganapathi & Grabowski, 1988; Ganapathi et al., 1986).
Support for this hypothesis is apparent when comparing
cytotoxicity results in Table I and the DOX accumulation
data in Figure 2. As an example, in B16-BL6/S cells treated
with O.5ugml-l ADR, drug levels of 120ng 10-6 cells
produce >95% kill, but in B16-BL6/DOXO.25 cells which
accumulate 2.5 times more ADR when treated with
5.0,ugml-1 ADR, cell kill is only 50%. Similar comparisons
with the other progressively DOX-resistant sublines also
demonstrate a lack of correlation between DOX levels and
cytotoxic response. The role of TFP in modulating cytotoxic
effects of DOX in the resistant cells also suggest that
alteration in gross cellular DOX levels do not contribute to
the magnitude of enhancement in cell kill. A specific example
would be the B16-BL6/DOXO.05 and B16-BL6/DOXO.25
cells wherein treatment with 1.Ojgml-l DOX+5,UM TFP
enhanced drug levels compared to 1.0 igml-l DOX alone
only by 1.2-fold, but cytotoxicity was increased 3-fold. In
related studies DOX retention at 120min in B16-BL6/S and
B16-BL6/DOXO.25 cells treated for 1 h with 1.Ojgml-l
DOX alone was 55% and 34% respectively. Although these
results may suggest resistance is due to diminished retention,
when TFP was present during accumulation but not reten-
tion as carried out with cytotoxicity studies, DOX retention
in B16-BL6/S and B16-BL6/DOXO.25 cells at 120min was
still only 54% and 40% respectively. It therefore appears
that in the absence or presence of TFP, there is little
correlation between cellular DOX levels and the associated
cytotoxicity in progressively DOX-resistant B16-BL6 cells.
Overall, comparison of our earlier observations with a
> 100-fold DOX-resistant model system (Ganapathi & Gra-
bowski, 1983) and the present results on cytotoxicity (Figure
1 and Table I) and DOX accumulation (Figure 2) in
progressively DOX-resistant cells suggest that the effects of
TFP in modulating cytotoxicity but not accumulation is
related to the degree of DOX-resistance.
The antitumour studies in mice though preliminary appear
promising and demonstrate that the effects of TFP in
modulating DOX cytotoxicity in vitro occur in vivo as well.
The magnitude of response in vivo with DOX plus TFP at
high levels of resistance with the B16-BL6/DOX0.25 cells
were not as encouraging as the in vitro results, and this may
be related to the fact that sufficiently high cellular levels of
DOX are not achieved at the maximally tolerated dose and
schedule of DOX used.
In summary, results from this study demonstrate that
there is little correlation between cellular accumulation of
DOX and magnitude of resistance in progressively DOX-
resistant B16-BL6 cells. The calmodulin inhibitor TFP was
appreciably more effective in enhancing cytotoxicity rather
than accumulation of DOX in the progressively resistant
sublines and the magnitude of TFP effects on DOX cyto-
toxicity was related to the level of resistance. The superior
chemotherapeutic efficacy in vivo of DOX plus TFP com-
pared to DOX alone against pulmonary metastases of DOX-
resistant B16-BL6 cells may be relevant to the recent demon-
stration (Miller et al., 1988) that TFP may be of therapeutic
value clinically in modulating the cytotoxicity of DOX in
tumours with acquired DOX-resistance.
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